Palvella Therapeutics Inc. (PVLA)
PVLA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$128.51
-4.37% on the day
Market cap
$1.9B
Small cap
Revenue
No annual revenue filed since the period ending 2023-12-31
Net income
No annual revenue filed since the period ending 2023-12-31
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | PVLA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001583648 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials
No annual revenue filed since the period ending 2023-12-31.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-02-26 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-08-04 |
| Latest current report | 8-K | 2026-08-04 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 809 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.8% |
| 1 month | -18.7% |
| 3 months | -16.8% |
| Year to date | +17.5% |
| 1 year | +61.4% |
| From 52-week high | -22.2% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MLYS | Mineralys Therapeutics Inc. | $21.00 | -5.53% | $1.9B |
| XERS | Xeris Biopharma Holdings Inc. | $10.20 | -2.49% | $1.9B |
| URGN | UroGen Pharma Ltd. | $38.26 | -0.05% | $1.9B |
| ADRX | ADARx Pharmaceuticals Inc. | $17.70 | -1.50% | $1.9B |
| AGIO | Agios Pharmaceuticals Inc. | $30.21 | -1.98% | $1.8B |
| LKFT | Lakefront Biotherapeutics | $29.05 | -1.76% | $1.9B |
| ZYME | Zymeworks Inc. | $25.07 | -1.03% | $1.8B |
| VERA | Vera Therapeutics Inc. | $26.79 | -3.35% | $1.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier